Implementing a Randomized Control Trial to Test the Expanded Web-based Decision Aid

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The overall goal of the randomized control trial (RCT) will be to evaluate the efficacy of modifications to a web-based tool for patient decision-making regarding return of genomic results that will more closely focus on rare cancers. Participants will be given access to a web-based decision aid (or a standard control) that guides participants in making decisions about what type of genomic results they would like to receive from testing performed in the PE-CGS study (NCT06340646).

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

∙ Eligibility Criteria:

• Enrolled in the WU-PE-CGS study (IRB#202106129); that eligibility entails:

‣ Diagnosis of cholangiocarcinoma

⁃ Diagnosis of multiple myeloma, must be African American

⁃ Diagnosis of colorectal cancer, must be African American and age 65 or older at time of diagnosis

• At least 18 years old.

• Able to understand an IRB-approved informed consent document and agree to participation

• Have access to a personal computer, tablet or mobile device

Locations
United States
Missouri
Washington University School of Medicine
RECRUITING
St Louis
Contact Information
Primary
Erin Linnenbringer, Ph.D., MS
elinnen@wustl.edu
314-747-1966
Backup
Bettina Drake, Ph.D., MPH
drakeb@wustl.edu
314-747-4534
Time Frame
Start Date: 2025-04-01
Estimated Completion Date: 2026-12-31
Participants
Target number of participants: 240
Treatments
Experimental: Intervention: Genetics Advisor Online Tool
The Intervention group will receive the expanded Genetics Advisor decision aid.
Active_comparator: Control: Standard developed materials
The control group will receive a description of each type of genomic sequencing result they could receive using the standard informed consent process for the return-of-results protocol.
Sponsors
Leads: Washington University School of Medicine
Collaborators: National Cancer Institute (NCI)

This content was sourced from clinicaltrials.gov